Xilio Therapeutics, Inc. (XLO) Misses Q3 EPS by 6c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
- Wall St on pace for higher open as oil pulls back ahead of Fed decision
- Meta's $97.5B AI money grab: why Zuckerberg is racing to raise cash before rivals
- Deutsche Bank’s Reid sees potential final dip this year before Santa rally
- UPS tops estimates as efficiency drive gains momentum
- GM to move stock listing to Nasdaq in November, shares gain
Tweet
Share
E-mail
Get Alerts XLO Hot Sheet
Join SI Premium – FREE
Xilio Therapeutics, Inc. (NASDAQ: XLO) reported Q3 EPS of ($0.11), $0.06 worse than the analyst estimate of ($0.05). Revenue for the quarter came in at $19.07 million versus the consensus estimate of $16.48 million.
For earnings history and earnings-related data on Xilio Therapeutics, Inc. (XLO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Meta's $97.5B AI money grab: why Zuckerberg is racing to raise cash before rivals
- UBS Reiterates Buy Rating on Bob's Discount Furniture (BOBS) on Long-Term Earnings Power
- Bloom Energy Corp. (BE) call put ratio 2.2 calls to 1 put as share price up 7.9
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
